Burden of rotavirus gastroenteritis and potential benefits of a pentavalent rotavirus vaccination in Belgium
Authors:
- Mélanie TrichardMTMélanie Trichard
- Nathalie LargeronNLNathalie Largeron
- Rachid RafiaRRRachid Rafia
- Stève BénardSBStève Bénard
- MdMDMd
- Pharm DPDPharm D
- MscMSMsc
- 1 January 2008
- journal article
- Published by Informa Healthcare in Journal of Medical Economics
- Vol. 11 (3) , 431-448
Abstract
A decision analytic model was built to assess the paediatric rotavirus gastroenteritis (RVGE) burden and potential benefits associated with the introduction of RotaTeq (pentavalent rotavirus vaccine) in Belgium. In the absence of a rotavirus (RV) immunisation programme, paediatric RVGE was estimated to account for about 5,860 hospitalisations, 1,720 cases of nosocomial infections, 9,410 cases treated by general practitioners/paediatricians (GP/P) and 10,790 cases not seeking medical care for a birth cohort followed up to 5 years of age. Paediatric RVGE was estimated to cost about euro9.0 million from the Belgian healthcare provider perspective and euro15.3 million to society. Given a 90% RV vaccination coverage rate, the pentavalent RV vaccine would have a high impact on RV burden by preventing more than 4,850 hospitalisations, 995 cases of nosocomial infections, 7,145 cases treated by GP/P and 8,190 cases not seeking medical care, and reduce RVGE costs by euro7.1 million from the Belgian healthcare provider perspective and euro12.0 million to society.Keywords
This publication has 27 references indexed in Scilit:
- Burden of paediatric rotavirus gastroenteritis and potential benefits of a universal rotavirus vaccination programme with RotaTeq® in FranceVaccine, 2007
- Costs of Community‐Acquired Pediatric Rotavirus Gastroenteritis in 7 European Countries: The REVEAL StudyThe Journal of Infectious Diseases, 2007
- Multicenter Prospective Study of the Burden of Rotavirus Acute Gastroenteritis in Europe, 2004–2005: The REVEAL StudyThe Journal of Infectious Diseases, 2007
- Rotavirus gastroenteritis: epidemiological data from a regional hospital in BelgiumEuropean Journal of Pediatrics, 2007
- Safety and Efficacy of a Pentavalent Human–Bovine (WC3) Reassortant Rotavirus VaccineNew England Journal of Medicine, 2006
- Vaccines for Rotavirus Gastroenteritis Universally Needed for InfantsPediatric Annals, 2004
- Economic impact of healthcare-associated rotavirus infection in a paediatric hospitalJournal of Hospital Infection, 2003
- Global Illness and Deaths Caused by Rotavirus Disease in ChildrenEmerging Infectious Diseases, 2003
- Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries1Prepared as a review for the Consensus Workshop on Rotavirus Vaccines for use in Developing Countries, Geneva, January 9–10, 1997. Sponsored by: The Global Programme for Vaccines, World Health Organization, The Children's Vaccine Initiative and the Centers for Disease Control and Prevention.1Vaccine, 1999
- Cost-effectiveness Analysis of a Rotavirus Immunization Program for the United StatesJAMA, 1998